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Stenting in Patients With Atrial Fibrillation*Deepak L. Bhatt, MD, MPHSEE PAGE 1619P atients with atrial ﬁbrillation needing stentspose one of the greatest challenges in car-diovascular medicine (1). The atrial ﬁbrillation
generally warrants anticoagulation, and dual anti-
platelet therapy is the established standard of care
for patients with stents (2–4). The predominant prac-
tice in patients with both indications has been to treat
with triple therapy (most commonly aspirin, clopi-
dogrel, and warfarin) for varying durations (5). The
WOEST (What Is the Optimal Antiplatelet and Antico-
agulant Therapy in Patients With Oral Anticoagula-
tion and Coronary Stenting) trial demonstrated that
triple therapy produced a large, but unsurprising
increase in bleeding compared with double therapy
with clopidogrel and warfarin, but no increases in
the number of ischemic or thromboembolic events
were detected in 573 patients (6). A recent Euro-
pean consensus document nicely summarized the*Editorials published in the Journal of the American College of Cardiology
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double and triple therapy for various durations,
although relatively sparse randomized data were
included to support the recommendations (7).In this issue of the Journal, Fiedler et al. (8)
presented the main results of the ISAR-TRIPLE (In-
tracoronary Stenting and Antithrombotic Regimen–
Testing of a 6-Week Versus a 6-Month Clopidogrel
Treatment Regimen in Patients With Concomitant
Aspirin and Oral Anticoagulant Therapy Following
Drug-Eluting Stenting) trial (8). This open-label study
randomized 614 patients with an indication for
oral anticoagulation (primarily atrial ﬁbrillation)
undergoing drug-eluting stent implantation to either
6 weeks or 6 months of triple therapy with aspirin,
clopidogrel, and warfarin, followed by double ther-
apy with aspirin and warfarin thereafter. There was
no signiﬁcant difference in the primary endpoint
of death, myocardial infarction (MI), deﬁnite stent
thrombosis, stroke, or Thrombolysis In Myocardial
Infarction (TIMI) major bleeding at 9 months: 9.8% in
the 6-week group versus 8.8% in the 6-month group
(hazard ratio: 1.14; 95% CI: 0.68 to 1.91; p ¼ 0.63).
There was also no signiﬁcant difference in the sec-
ondary combined ischemic endpoint of cardiac death,
MI, deﬁnite stent thrombosis, or ischemic stroke,
although there were few events (12 vs. 13). Similarly,
there was no difference in the secondary bleeding
endpoint of TIMI major bleeding (16 vs. 12 events).
However, more sensitive metrics of bleeding did
ﬁnd a beneﬁt of the shorter duration of triple therapy.
In a landmark analysis of any bleeding from 6 weeks
to 6 months according to the Bleeding Academic
Research Consortium deﬁnition types 1 to 5 (9), there
was a signiﬁcant reduction in bleeding: 13.1%
versus 21.8% (hazard ratio: 0.57; p ¼ 0.01). The open-
label design and differences in clopidogrel prescrip-
tion or adherence may have somewhat diluted the
FIGURE 1 WOEST and ISAR-TRIPLE Data Showing Effects on
Cardiovascular Events and Any Bleeding Events of Shorter-
Duration Triple Therapy (0 or 6 weeks, respectively) Versus
Longer-Duration Triple Therapy (12 or 6months, respectively)
A consistency of results favors the shorter duration. HR ¼ hazard
ratio; ISAR-TRIPLE ¼ Intracoronary Stenting and Antithrombotic
Regimen–Testing of a 6-Week Versus a 6-Month Clopidogrel
Treatment Regimen in Patients With Concomitant Aspirin and
Oral Anticoagulant Therapy Following Drug-Eluting Stenting;
WOEST ¼ What Is the Optimal Antiplatelet and Anticoagulant
Therapy in Patients With Oral Anticoagulation and Coronary
Stenting.
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1631contrast between the 2 treatment arms, diminishing
the observed bleeding beneﬁt of shorter-duration
triple therapy (and also potentially obscuring a
beneﬁt of longer-duration triple therapy on throm-
botic complications).
In patients on triple therapy, use of prophylactic
proton pump inhibition is recommended (although it
was used in <40% of the patients in the ISAR-
TRIPLE trial) (10,11). The aspirin dose used should
be no greater than 100 mg, and, to reduce the
gastrointestinal bleeding risk, patients should avoid
or minimize use of nonsteroidal anti-inﬂammatory
drugs to the extent possible. To date, warfarin has
been the oral anticoagulant agent most used as part
of triple therapy, and some experts recommend
trying to target an international normalized ratio of
2.0 to 2.5. Use of the novel oral anticoagulant agents
instead of warfarin in trials of nonvalvular atrialﬁbrillation is clearly associated with less intracranial
hemorrhage, but there does appear to be at least a
signal of excess gastrointestinal bleeding, which is a
more frequent cause of major bleeding than intra-
cranial bleeding, as also noted in the ISAR-TRIPLE
trial (12).
There are 2 large ongoing trials that should help
deﬁne the optimal cocktail and duration of antith-
rombotic agent treatment in patients with atrial
ﬁbrillation and recent stents. The PIONEER AF-
PCI (Study Exploring Two Strategies of Rivaroxaban
and One of Oral Vitamin K Antagonist in Patients
With Atrial Fibrillation Who Undergo Percuta-
neous Coronary Intervention) trial (NCT01830543)
will randomize more than 2,000 patients to 1 of 3
combination regimens. The REDUAL-PCI (Evaluation
of Dual Therapy With Dabigatran vs. Triple Therapy
With Warfarin in Patients With AF That Undergo a PCI
With Stenting) trial (NCT02164864) will randomize
more than 8,000 patients to 1 of 3 combination arms.
There are many patients who are eligible for these
trials. It is a population that doctors often lament is
very common, but there is great uncertainty about the
correct treatment. However, this population can be
challenging to enroll in clinical trials, and it will be
important for physicians to actually support these
studies for a deﬁnitive answer to be produced.
Otherwise, this will be an area that continues to be
driven by opinion, instead of by large randomized
data sets.
Until such data become available and outside of
clinical trials, it is very reasonable to adopt the gen-
eral strategy supported by the ISAR-TRIPLE trial,
and by the WOEST study, which is to abbreviate
the duration of triple antithrombotic therapy. Double
therapy does seem to beat extended-duration triple
therapy (Figure 1). Whether that duration of triple
therapy should be 0, 4, 6, or 12 weeks, or even longer
is uncertain and may be inﬂuenced by ischemic,
thromboembolic, and bleeding risks. On the basis
of the ISAR-TRIPLE study, 6 weeks certainly seems
like a reasonable starting point, titrating the dura-
tion and intensity of triple antithrombotic therapy
upward or downward, depending on patient and le-
sion characteristics.
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